Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

ConclusionAcross all degrees of severity for baricitinib 2 mg and 4 mg doses, the proportion of patients responding was yet to plateau up to week 52. Response to treatment was longer for patients with a baseline SALT score 95–100. Further studies are needed to analyze other parameters that may impact observed response rates.

http://rd.springer.com/10.1007/s13555-023-01033-8

Source: Dermatology and Therapy - September 23, 2023 Category: Dermatology Source Type: research